External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

Hernández, Virginia; Peña, Enrique de la; Martín, M.D.; Blázquez, C.; Díaz, Francisco Javier; Llorente, C.

doi:10.1007/s00345-010-0635-2

Cited by 55 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9,10] Second-look TUR has gained attention because of the inaccuracy of the pathological diagnosis. [11][12][13] Hernandez et al [14] and Pillai et al [15] conducted different trials to evaluate external validity and applicability of the EORTC risk tables. Due to the sample size of the trial, Hernandez et al [14] could only validate the recurrence model of the EORTC algorithm and Pillai et al [15] were not able to validate the proposed algorithm in their patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, the patient characteristics of other trials were similar to the current study's patient characteristics. [14,15] In contrast to Sylvester's study which had been done in industrialized world, Turkey which is included among the developing countries, has lack of organized health care and a large portion of the patients have significant socioeconomic problems in accessing a convenient health center. As such, increase in the cases with histopathological diagnosis of high grade bladder tumor and concomitant CIS were observed with time.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Kılınç¹,

Bayar²,

Dalkılıç³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: To evaluate the consistency of the results of patients who were treated for non-muscle-invasive bladder cancer (NMIBC) in our clinic with the European Organization for Research and Treatment of Cancer (EORTC) risk table.Material and methods: Data were retrospectively analyzed from 452 patients who had undergone transurethral resection of bladder tumor (TUR-BT) between the years 2002, and 2010 for primary or recurrent NMIBC. Our study had a retrospective design but based on prospective cohort study. Patients were staged according to the 2002 Tumor Node Metastasis (TNM) classification and the 1973 World Health Organization grading system. Recurrence was defined as non-muscle-invasive or muscle-invasive and progression as muscle-invasive tumor determined based on following cystoscopy and TUR-BT results, and confirmed by histopathologic analysis. Patients in the current study were classified into four groups according to the EORTC risk tables. Time to first recurrence and progression was determined for each risk group. Results:Of the 452 patients, 348 were enrolled in this study. The overall mean follow-up period was 55.25 months of all patients. Of 348 patients, 130 (37.4%) and 258 patients (74.1%) had recurrence after treatment at the 1 and 5 year follow-up period, respectively. While 35 (10.1%) and 99 patients (28.4%) progressed to muscle-invasive cancer at the 1 and 5 year follow-up period, respectively. In the multivariate analysis, grade, number, size of the tumor size, and concomitant carcinoma in situ were found to be statistically significant for disease progression and recurrence. Conclusion:When EORTC risk tables were comparatively evaluated in our patient population, we can say that EORTC tables predict nearly accurately the clinical course of patients with NMIBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Kılınç¹,

Bayar²,

Dalkılıç³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…In terms of the EORTC table, several external validation studies were carried out. [4][5][6][7][8][9] Among them, the CUETO group validated the EORTC table using a dataset from the CUETO scoring system. 7 Their results showed that the EORTC tables overestimated the risk of recurrence in all risk groups, as well as the probabilities of progression in higher-risk patients.…”

Section: Discussionmentioning

confidence: 99%

External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin

et al. 2014

View full text Add to dashboard Cite

Abbreviations & AcronymsObjective: To validate two prediction models (European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment) for recurrence and progression of non-muscle invasive bladder cancer in Japanese patients who underwent bacillus Calmette-Guérin instillation therapy. Methods: From March 1985 to April 2007, data were analyzed from 366 patients who underwent transurethral resection of bladder tumor followed by bacillus Calmette-Guérin instillation therapy. The ability of two scoring models to predict recurrence and progression was assessed by concordance index. Results: For recurrence probability, the concordance index of the European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment models was 0.514 and 0.576, respectively, which was lower than that (0.604) of a selected single prognostic factor (age) by our multivariate analysis. For progression probability, the concordance index of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment models was 0.693 and 0.764, respectively, which was higher than that (0.633) of a selected single factor (T stage) by our multivariate analysis. The Spanish Urological Club for Oncological Treatment scoring system resulted in better stratification of tumor recurrence and progression when compared with the European Organization for Research and Treatment of Cancer model, probably because more patients underwent bacillus Calmette-Guérin treatment in the Spanish Urological Club for Oncological Treatment cohort than in the European Organization for Research and Treatment of Cancer cohort. Conclusions: The Spanish Urological Club for Oncological Treatment scoring system is a good predictor of tumor recurrence and progression in Japanese patients who underwent bacillus Calmette-Guérin immunotherapy. A large prospective study is warranted to confirm the efficacy of this system.

show abstract

“…However, in this series, a low number of patients (n = 230) with only primary NMIBC was analyzed, and therefore a full validation could not be done. Hernandez et al recently reported a validation of EORTC tables for recurrence in 417 patients in follow-up with primary TaT1 bladder tumors [7]. Nevertheless, validation of the EORTC risk tables still has not been reported in a large cohort of patients.…”

Section: Introductionmentioning

confidence: 99%

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

et al. 2011

View full text Add to dashboard Cite

External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

Abstract: In terms of the applicability of the EORTC risk tables in our patients' population, we conclude that these tables predict accurately the clinical course of patients with NMIBC. Due to the sample size of our study, we can only validate the recurrence model of the EORTC tables.

Cited by 55 publications

References 20 publications

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

Contact Info

Product

Resources

About